Wambeke David J. 4

What Happened David J. Wambeke, Chief Business Officer of NeuroOne Medical Technologies (NMTC), purchased 1,000,000 shares on March 1, 2026 at $0.67 per share in a P (purchase) transaction — reported value $670,400. He was also granted 500,000 shares in an A (award/grant) transaction priced at $0.00 (derivative/restricted award). The cash purchase is a direct buy (more informative to investors); the award is subject to vesting.

Key Details

• Transaction dates: March 1, 2026; Form 4 filed March 3, 2026 (appears timely — Form 4 is generally due within two business days).
• Purchase: 1,000,000 shares at $0.67, total reported $670,400 (code P — purchase).
• Award: 500,000 shares at $0.00 (code A — grant/derivative).
• Vesting (footnote): 25% vests March 1, 2027; remaining 75% vests in 12 equal installments on the last day of each quarter beginning March 31, 2027.
• Shares owned after the transactions: not specified in the provided excerpt — see the full Form 4 for total holdings.
• No indication in the filing of a 10b5-1 plan, tax withholding, or immediate sale of any newly acquired shares.

Context

• The purchase is a straightforward insider buy (can signal confidence but is not proof of future performance). The grant is typical of retention/compensation packages and will vest over time, so those shares are not immediately transferable.
• As always, filings are factual records of transactions — they do not explain the insider’s motivation. Check the full Form 4 for exact post-transaction holdings and any additional notes.